Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 109, Issue 2, Pages 319-333Publisher
WILEY
DOI: 10.1002/cpt.2137
Keywords
-
Categories
Ask authors/readers for more resources
After certain drugs were withdrawn from the market due to the risk of drug-induced torsade de pointes (TdP), the ICH released guidelines focusing on the assessment of surrogate biomarkers for TdP in 2005. Vargas et al. proposed that double-negative nonclinical data may not require detailed clinical QTc evaluation due to low probability of QTc prolongation and TdP, leading to the ICH releasing a new Draft Guideline to address this. The ICH's new guidelines aim to reduce Thorough QT (TQT) studies using double-negative nonclinical data and achieving a low-risk determination in situations where TQT studies are not feasible.
After multiple drugs were removed from the market secondary to drug-induced torsade de pointes (TdP) risk, the International Council for Harmonisation (ICH) released guidelines in 2005 that focused on the nonclinical (S7B) and clinical (E14) assessment of surrogate biomarkers for TdP. Recently, Vargas et al. published a pharmaceutical-industry perspective making the case that double-negative nonclinical data (negative in vitro hERG and in vivo heart-rate corrected QT (QTc) assays) are associated with such low probability of clinical QTc prolongation and TdP that potentially all double-negative drugs would not need detailed clinical QTc evaluation. Subsequently, the ICH released a new E14/S7B Draft Guideline containing Questions and Answers (Q&As) that defined ways that double-negative nonclinical data could be used to reduce the number of Thorough QT (TQT) studies and reach a low-risk determination when a TQT or equivalent could not be performed. We review the Vargas et al. proposal in the context of what was contained in the ICH E14/S7B Draft Guideline and what was proposed by the ICH E14/S7B working group for a stage 2 of updates (potential expanded roles for nonclinical data and details for assessing TdP risk of QTc-prolonging drugs). Although we do not agree with the exact probability statistics in the Vargas et al. paper because of limitations in the underlying datasets, we show how more modest predictive value of individual assays could still result in low probability for TdP with double-negative findings. Furthermore, we expect that the predictive value of the nonclinical assays will improve with implementation of the new ICH E14/S7B Draft Guideline.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available